Abstract
Background The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria through the formulation of Millennium Development Goal (MDG) 6. The Global Burden of Disease 2013 study provides a consistent and comprehensive approach to disease estimation for between 1990 and 2013, and an opportunity to assess whether accelerated progress has occured since the Millennium Declaration. Methods To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model appropriately modifi ed based on a systematic review of available studies of mortality with and without antiretroviral therapy (ART). For concentrated epidemics, we calibrated Spectrum models to fi t vital registration data corrected for misclassifi cation of HIV deaths. In generalised epidemics, we minimised a loss function to select epidemic curves most consistent with prevalence data and demographic data for all-cause mortality. We analysed counterfactual scenarios for HIV to assess years of life saved through prevention of mother-to-child transmission (PMTCT) and ART. For tuberculosis, we analysed vital registration and verbal autopsy data to estimate mortality using cause of death ensemble modelling. We analysed data for corrected case-notifi cations, expert opinions on the case-detection rate, prevalence surveys, and estimated cause-specifi c mortality using Bayesian meta-regression to generate consistent trends in all parameters. We analysed malaria mortality and incidence using an updated cause of death database, a systematic analysis of verbal autopsy validation studies for malaria, and recent studies (2010-13) of incidence, drug resistance, and coverage of insecticide-treated bednets. Findings Globally in 2013, there were 1·8 million new HIV infections (95% uncertainty interval 1·7 million to 2·1 million), 29·2 million prevalent HIV cases (28·1 to 31·7), and 1·3 million HIV deaths (1·3 to 1·5). At the peak of the epidemic in 2005, HIV caused 1·7 million deaths (1·6 million to 1·9 million). Concentrated epidemics in Latin America and eastern Europe are substantially smaller than previously estimated. Through interventions including PMTCT and ART, 19·1 million life-years (16·6 million to 21·5 million) have been saved, 70·3% (65·4 to 76·1) in developing countries. From 2000 to 2011, the ratio of development assistance for health for HIV to years of life saved through intervention was US$4498 in developing countries. Including in HIV-positive individuals, all-form tuberculosis incidence was 7·5 million (7·4 million to 7·7 million), prevalence was 11·9 million (11·6 million to 12·2 million), and number of deaths was 1·4 million (1·3 million to 1·5 million) in 2013. In the same year and in only individuals who were HIV-negative, all-form tuberculosis incidence was 7·1 million (6·9 million to 7·3 million), prevalence was 11·2 million (10·8 million to 11·6 million), and number of deaths was 1·3 million (1·2 million to 1·4 million). Annualised rates of change (ARC) for incidence, prevalence, and death became negative after 2000. Tuberculosis in HIV-negative individuals disproportionately occurs in men and boys (versus women and girls); 64·0% of cases (63·6 to 64·3) and 64·7% of deaths (60·8 to 70·3). Globally, malaria cases and deaths grew rapidly from 1990 reaching a peak of 232 million cases (143 million to 387 million) in 2003 and 1·2 million deaths (1·1 million to 1·4 million) in 2004. Since 2004, child deaths from malaria in sub-Saharan Africa have decreased by 31·5% (15·7 to 44·1). Outside of Africa, malaria mortality has been steadily decreasing since 1990. Interpretation Our estimates of the number of people living with HIV are 18·7% smaller than UNAIDS's estimates in 2012. The number of people living with malaria is larger than estimated by WHO. Incidence rates for HIV, tuberculosis, and malaria have all decreased since 2000. At the global level, upward trends for malaria and HIV deaths have been reversed and declines in tuberculosis deaths have accelerated. 101 countries (74 of which are developing) still have increasing HIV incidence. Substantial progress since the Millennium Declaration is an encouraging sign of the effect of global action. Funding Bill & Melinda Gates Foundation.
Original language | English |
---|---|
Pages (from-to) | 1005-1070 |
Number of pages | 66 |
Journal | Lancet |
Volume | 384 |
Issue number | 9947 |
DOIs | |
Publication status | Published - 2014 |
Fingerprint
Dive into the research topics of 'Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Lancet, Vol. 384, No. 9947, 2014, p. 1005-1070.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
AU - Murray, Christopher
AU - Ortblad, Katrina
AU - Guinovart, Caterina
AU - Lim, Stephen
AU - Wolock, Timothy
AU - Roberts, Allan
AU - Dansereau, Emily
AU - Graetz, Nicholas
AU - Barber, Ryan
AU - Brown, Jonathan
AU - wang, Haidong
AU - Duber, Herbert
AU - Naghavi, Mohsen
AU - Dicker, Daniel
AU - Dandona, Lalit
AU - Salomon, Joshua
AU - Heuton, Kyle
AU - Foreman, Kyle
AU - Phillips, David
AU - Fleming, Thomas
AU - Flaxman, Abraham
AU - Phillips, Bryan
AU - Johnson, Elizabeth
AU - Coggeshall, Megan
AU - Allah, Foad
AU - Abera, Semaw
AU - Abraham, Jerry
AU - Abubaka, Ibrahim
AU - Abu-Raddad, Laith
AU - Abu-Rmeileh, Niveen
AU - Achoki, Tom
AU - Adeyemo, Austine
AU - Adou, Arsene
AU - Adsua, Jose
AU - Agardh, Emilie
AU - Akena, Dickens
AU - Kahbouri, Mazin
AU - Alasfoor, Deena
AU - Albittar, Mohammed
AU - Alcala-Cerra, Gabriel
AU - Alegretti, Miguel
AU - Alemu, Zewdie
AU - Alfonso-Cristancho, Rafael
AU - Alhabib, Samia
AU - Ali, Raghib
AU - Alla, Francois
AU - Allen, Peter
AU - Alsharif, Ubai
AU - Alvarez, Elena
AU - Alvis-Guzman, Nelson
AU - Amankwaa, Adansi
AU - Amare, Azmeraw
AU - Amini, Hassan
AU - Ammar, Walid
AU - Anderson, Benjamin
AU - Antonio, Carl
AU - Arsenijevic, Valentina
AU - Artaman, Ali
AU - Asghar, Rana
AU - Assadi, Reza
AU - Atkins, Lydia
AU - Badawi, Alaa
AU - Balakrishnan, Kalpana
AU - Banerjee, Amitava
AU - Basu, Sanjay
AU - Beardsley, Justin
AU - Bekele, Tolesa
AU - Bell, Michelle
AU - Bernabe, Eduardo
AU - Beyene, Tariku
AU - Bhala, Neeraj
AU - Bhalla, Ashish
AU - Bhutta, Zulfiqar
AU - Bin Abdulhak, Aref
AU - Binagwaho, Agnes
AU - Blore, Jed
AU - Basara, Berrak
AU - Bose, Dipan
AU - Brainin, Michael
AU - Breitborde, Nicholas
AU - Castañeda-Orjuela, Carlos
AU - Catalá-López, Ferrán
AU - Chadha, Vineet
AU - Chang, Jung-Chen
AU - Chiang, Peggy
AU - Chuang, Ting-Wu
AU - Colomar, Mercedes
AU - Cooper, Leslie
AU - Cooper, Cyrus
AU - Courville, Karen
AU - Cowie, Benjamin
AU - Criqui, Michael
AU - Dandona, Rakhi
AU - Dayama, Anand
AU - De Leo, Diego
AU - Pozo-Cruz, Borja
AU - Deribe, Kebede
AU - Jarlais, Don
AU - Dessalegn, Muluken
AU - Dharmaratne, Samath
AU - Dilmen, Ugur
AU - Ding, Eric
AU - Driscoll, Tim
AU - Durrani, Adnan
AU - Ellenbogen, Richard
AU - Ermakov, Sergey
AU - Esteghamati, Alireza
AU - Faraon, Emerito
AU - Farzadfar, Farshad
AU - Fereshtehnejad, Seyed-Mohammad
AU - Fijabi, Daniel
AU - Forouzanfar, Mohammad
AU - Fra.Paleo, Urbano
AU - Gaffikin, Lynne
AU - Gamkrelidze, Amiran
AU - Gankpé, Fortuné
AU - Geleijnse, Johanna
AU - Gessner, Bradford
AU - Gibney, Katherine
AU - Ginawi, Ibrahim
AU - Glaser, Elizabeth
AU - Gona, Philimon
AU - Goto, Atsushi
AU - Gouda, Hebe
AU - Gugnani, Harish
AU - Gupta, Rajeev
AU - Gupta, Rahul
AU - Hafezi-Nejad, Nima
AU - Hamadeh, Randah
AU - Hammami, Mouhanad
AU - Hankey, Graeme
AU - Harb, Hilda
AU - Haro, Josep
AU - Havmoeller, Rasmus
AU - Hay, Simon
AU - Hedayati, Mohammad
AU - Pi, Ileana
AU - Hoek, Hans
AU - Hornberger, John
AU - Hosgood, H
AU - Hotez, Peter
AU - Hoy, Damian
AU - Huang, John
AU - Iburg, Kim
AU - Idrisov, Bulat
AU - Innos, Kaire
AU - Jacobsen, Kathryn
AU - Jeemon, Panniyammakal
AU - Jensen, Paul
AU - Jha, Vivekanand
AU - Jiang, Guohong
AU - Jonas, Jost
AU - Juel, Knud
AU - Kan, Haidong
AU - Kankindi, Ida
AU - Karam, Nadim
AU - Karch, André
AU - Karema, Corine
AU - Kaul, Anil
AU - kawakami, Norito
AU - Kazi, Dhruv
AU - Kemp, Andrew
AU - Kengne, Andre
AU - Keren, Andre
AU - Kereselidze, Maia
AU - Khader, Yousef
AU - Khalifa, Shams
AU - Khan, Ejaz
AU - Khang, Young-Ho
AU - Khonelidze, Irma
AU - KINFU, Yohannes
AU - Kinge, Jonas
AU - Knibbs, Luke
AU - Kokubo, Yoshihiro
AU - Kosen, S
AU - Defo, Barthelemy
AU - Kulkarni, Veena
AU - Kulkarni, Chanda
AU - Kumar, Kaushalendra
AU - Kumar, Ravi
AU - Kumar, G
AU - Kwan, Gene
AU - Lai, Taavi
AU - Balaji, Arjun
AU - Lam, Hilton
AU - Lan, Qing
AU - Lansingh, Van
AU - Larson, Heidi
AU - Larsson, Anders
AU - Lee, Jong-Tae
AU - Leigh, James
AU - Leinsalu, Mall
AU - Leung, Ricky
AU - Li, Yichong
AU - Li, Yongmei
AU - De Lima, Graça
AU - Lin, Hsien-Ho
AU - Lipshultz, Steven
AU - Liu, Shiwei
AU - Liu, Yang
AU - Lloyd, Belinda
AU - Lotufo, Paulo
AU - Machado, Vasco
AU - Maclachlan, Jennifer
AU - Magis-Rodriguez, Carlos
AU - Majdan, Marek
AU - Mapoma, Christopher
AU - Marcenes, wagner
AU - Marzan, Melvin
AU - Masci, Joseph
AU - Mashal, Mohammad
AU - Mason-Jones, Amanda
AU - Mayosi, Bongani
AU - Mazorodze, Tasara
AU - Mckay, Abigail
AU - Meaney, Peter
AU - Mehndiratta, Man
AU - Mejia-Rodriguez, Fabiola
AU - Melaku, Yohannes
AU - memish, Ziad
AU - Mendoza, Walter
AU - Miller, Ted
AU - Mills, Edward
AU - Mohammad, Karzan
AU - Mokdad, Ali
AU - Mola, Glen
AU - Monasta, Lorenzo
AU - Montico, Marcella
AU - Moore, Ami
AU - Mori, Rintaro
AU - Moturi, Wilkister
AU - Mukaigawara, Mitsuru
AU - Murthy, Kinnari
AU - Naheed, Aliya
AU - Naidoo, Kovin
AU - Naldi, Luigi
AU - Nangia, Vinay
AU - Narayan, K
AU - Nash, Denis
AU - Nejjari, Chakib
AU - Nelson, Robert
AU - Neupane, Sudan
AU - Newton, Charles
AU - Ng, Marie
AU - Nisar, Muhammad
AU - Nolte, Sandra
AU - Norheim, Ole
AU - Nowaseb, Vincent
AU - Nyakarahuka, Luke
AU - Oh, In-Hwan
AU - Ohkubo, Takayoshi
AU - Olusanya, Bolajoko
AU - Omer, Saad
AU - Opio, John
AU - Orisakwe, Orish
AU - Pandian, Jeyaraj
AU - Papachristou, Christina
AU - Caicedo, Angel
AU - Patten, Scott
AU - Paul, Vinod
AU - Pavlin, Boris
AU - Pearce, Neil
AU - Pereira, David
AU - Pervaiz, Aslam
AU - Pesudovs, Konrad
AU - Petzold, Max
AU - Pourmalek, Farshad
AU - Qato, Dima
AU - Quezada, Amado
AU - Quistberg, D
AU - Rafay, Anwar
AU - Rahimi, Kazem
AU - Rahimi-Movaghar, Vafa
AU - Rahman, Sajjad
AU - Raju, Murugesan
AU - Rana, Saleem
AU - Razavi, Homie
AU - Reilly, Robert
AU - Remuzzi, Giuseppe
AU - Richardus, Jan
AU - Ronfani, Luca
AU - Roy, Nobhojit
AU - Sabin, Nsanzimana
AU - Saeedi, Mohammad
AU - Sahraian, Mohammad
AU - Samonte, Genesis
AU - Sawhney, Monika
AU - Schneider, Ione
AU - Schwebel, David
AU - Seedat, Soraya
AU - Sepanlou, Sadaf
AU - Servan-Mori, Edson
AU - Sheikhbahaei, Sara
AU - Shibuya, Kenji
AU - Shiue, Ivy
AU - Shivakoti, Rupak
AU - Sigfusdottir, Inga
AU - Silberberg, Donald
AU - Silva, Andrea
AU - Simard, Edgar
AU - Singh, Jasvinder
AU - Skirbekk, Vegard
AU - Sliwa, Karen
AU - Soneji, Samir
AU - Soshnikov, Sergey
AU - Sreeramareddy, Chandrashekhar
AU - Stathopoulou, Vasiliki
AU - Stroumpoulis, Konstantinos
AU - Swaminathan, Soumya
AU - Sykes, Bryan
AU - Tabb, Karen
AU - Talongwa, Roberto
AU - Tenkorang, Eric
AU - Tenkorang, Eric
AU - Terkawi, Abdullah
AU - Thomson, Alan
AU - Thorne-Lyman, Andrew
AU - Towbin, Jeffrey
AU - Traebert, Jefferson
AU - Tran, Bach
AU - Dimbuene, Zacharie
AU - Tsilimbaris, Miltiadis
AU - Uchendu, Uche
AU - Ukwaja, Kingsley
AU - Uzun, Selen
AU - Vallely, Andrew
AU - Vasankari, Tommi
AU - Venketasubramanian, N
AU - Violante, Francesco
AU - Vlassov, Vasiliy
AU - Vollset, Stein
AU - Waller, Stephen
AU - Wallin, Mitchell
AU - Wang, Linhong
AU - Wang, XiaoRong
AU - Wang, Yanping
AU - Weichenthal, Scott
AU - Weiderpass, Elisabete
AU - Weintraub, Robert
AU - Westerman, Ronny
AU - White, Richard
AU - Wilkinson, James
AU - Williams, Thomas
AU - Woldeyohannes, Solomon
AU - Wong, John
AU - Xu, Gelin
AU - Yang, Yang
AU - Yano, Yuichiro
AU - Yentur, Gokalp
AU - Yip, Paul
AU - Yonemoto, Naohiro
AU - Yoon, Seok-Jun
AU - Youni, Mustafa
AU - Yu, Chuanhua
AU - Jin, Kim
AU - Zaki, Maysaa
AU - Zhao, Yong
AU - Zheng, Yingfeng
AU - Zhou, Maigeng
AU - Zhu, Jun
AU - Zou, Xiao
AU - lopez, Alan
AU - Vos, Theo
AU - al.,, et
N1 - Funding Information: We thank the countless individuals who have contributed to the Global Burden of Disease Study 2013 in various capacities. We would like to acknowledge the extensive support from all staff members at the Institute for Health Metrics and Evaluation and specifically thank: Michael F MacIntyre, Peter Speyer, and Summer Lockett Ohno for their management of the Global Burden of Disease Study 2013; Kelsey Pierce for her valuable assistance; Peter Speyer, James Bullard, Serkan Yalcin, Edgar Sioson, Evan Laurie, Charles Atkinson, and Andrew Ernst for their tireless support of the computational infrastructure necessary to produce the results; Linda A Ettinger for her expert administrative support; Peter Speyer, Abigail McLain, James Hancock, Marissa Iannarone, and Eden Stork for their persistent and invaluable work to gain access to and catalogue as much data as possible to inform the estimates; Stan Biryukov for his assistance with the tuberculosis database; Henry Apfel and Madeline Moyer for data extraction and processing; Christopher Margono, Michelle Subart, Lavanya Singh and Margaret Lind for assistance with galleys; Matthew M Coates, Carly E Levitz, Chelsea A Lidell, Meghan D Mooney, and Austin E Schumaker for production of all-cause mortality estimates; Amelia Bertozzi-Villa for review of Python coding of the Spectrum model. We would also like to acknowledge Mary Mahy, Keith Sabin and John Stover for sharing the UNAIDS EPP files with us and especially John Stover for responding to multiple queries regarding Spectrum. Additionally, Ibrahim Abubakar would like to acknowledge the UK National Institute for Health Research and MRC for funding. Laith J Abu-Raddad would like to acknowledge the support of Qatar National Research Fund (NPRP 04-924-3-251) who provided the main funding for generating the data provided to the GBD-IHME effort. Gabriel Alcalá-Cerra would like to acknowledge institutional support from Health Sciences and Neurosciences (CISNEURO) Research Group. Louisa Degenhardt is supported by an Australian National Health and Medical Research Council Principal Research Fellowship ( #1041742 ). Dr. Des Jarlais would like to acknowledge funding from NIH Grant DA R01 003574 . KD is supported by a Wellcome Trust Fellowship in Public Health and Tropical Medicine [ grant number 099876 ]. Prof. Giuseppe Remuzzi would like to acknowledge the International Society of Nephrology (ISN) for their support of his involvement in the GBD 2013. JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110 , National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891 , National Institute of Aging (NIA) U01 AG018947 , National Cancer Institute (NCI) U10 CA149950 , and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. Dr. Soneji was supported by the National Center for Advancing Translational Sciences grant number KL2TR001088. Karen M Tabb would like to acknowledge her current support: Lemann Institute Faculty Research Grant, University of Illinois. Andrew J Vallely is supported by a Training Fellowship from the National Health and Medical Research Council (NHMRC), Australia. Gelin Xu is currently funded by the Nature Science Foundation of China ( NSFC, 81070922 ). No individuals acknowledged received additional compensation for their efforts. Funding Information: CC has received consultancy, lecture fees and honoraria from AMGEN, GSK, Alliance for Better Bone Health, MSD, Eli Lilly, Pfizer, Novartis, Servier, Merck, Medtronic and Roche. LD has been funded by and acted as a consultant to UNAIDS, UNODC, and WHO. BD Gessner works for AMP which receives grant specific support from Crucell, GSK, Novartis, Pfizer, and Sanofi Pasteur and unrestricted support from Sanofi Pasteur all for work on vaccines and vaccine preventable diseases. Related to the current work, AMP receives grant support from GSK for work on issues related to malaria vaccines. KBG received the NHMRC-Gustav Nossal scholarship sponsored by CSL in 2012. This award is peer-reviewed through the standard NHMRC peer-review process; CSL played no part in selection of the awardee. PJ is supported by a career development fellowship from the Wellcome Trust, Public Health Foundation of India and a Consortium of United Kingdom Universities. Walter Mendoza is program analyst at the UNFPA country office in Peru, which not necessarily endorses the study. JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron and Allergan. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. Funding Information: We thank the countless individuals who have contributed to the Global Burden of Disease Study 2013 in various capacities. We would like to acknowledge the extensive support from all staff members at the Institute for Health Metrics and Evaluation and specifically thank: Michael F MacIntyre, Peter Speyer, and Summer Lockett Ohno for their management of the Global Burden of Disease Study 2013; Kelsey Pierce for her valuable assistance; Peter Speyer, James Bullard, Serkan Yalcin, Edgar Sioson, Evan Laurie, Charles Atkinson, and Andrew Ernst for their tireless support of the computational infrastructure necessary to produce the results; Linda A Ettinger for her expert administrative support; Peter Speyer, Abigail McLain, James Hancock, Marissa Iannarone, and Eden Stork for their persistent and invaluable work to gain access to and catalogue as much data as possible to inform the estimates; Stan Biryukov for his assistance with the tuberculosis database; Henry Apfel and Madeline Moyer for data extraction and processing; Christopher Margono, Michelle Subart, Lavanya Singh and Margaret Lind for assistance with galleys; Matthew M Coates, Carly E Levitz, Chelsea A Lidell, Meghan D Mooney, and Austin E Schumaker for production of all-cause mortality estimates; Amelia Bertozzi-Villa for review of Python coding of the Spectrum model. We would also like to acknowledge Mary Mahy, Keith Sabin and John Stover for sharing the UNAIDS EPP files with us and especially John Stover for responding to multiple queries regarding Spectrum. Additionally, Ibrahim Abubakar would like to acknowledge the UK National Institute for Health Research and MRC for funding. Laith J Abu-Raddad would like to acknowledge the support of Qatar National Research Fund (NPRP 04-924-3-251) who provided the main funding for generating the data provided to the GBD-IHME effort. Gabriel Alcalá-Cerra would like to acknowledge institutional support from Health Sciences and Neurosciences (CISNEURO) Research Group. Louisa Degenhardt is supported by an Australian National Health and Medical Research Council Principal Research Fellowship ( #1041742 ). Dr. Des Jarlais would like to acknowledge funding from NIH Grant DA R01 003574 . KD is supported by a Wellcome Trust Fellowship in Public Health and Tropical Medicine [ grant number 099876 ]. Prof. Giuseppe Remuzzi would like to acknowledge the International Society of Nephrology (ISN) for their support of his involvement in the GBD 2013. JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110 , National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891 , National Institute of Aging (NIA) U01 AG018947 , National Cancer Institute (NCI) U10 CA149950 , and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. Dr. Soneji was supported by the National Center for Advancing Translational Sciences grant number KL2TR001088. Karen M Tabb would like to acknowledge her current support: Lemann Institute Faculty Research Grant, University of Illinois. Andrew J Vallely is supported by a Training Fellowship from the National Health and Medical Research Council (NHMRC), Australia. Gelin Xu is currently funded by the Nature Science Foundation of China ( NSFC, 81070922 ). No individuals acknowledged received additional compensation for their efforts.
PY - 2014
Y1 - 2014
N2 - Background The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria through the formulation of Millennium Development Goal (MDG) 6. The Global Burden of Disease 2013 study provides a consistent and comprehensive approach to disease estimation for between 1990 and 2013, and an opportunity to assess whether accelerated progress has occured since the Millennium Declaration. Methods To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model appropriately modifi ed based on a systematic review of available studies of mortality with and without antiretroviral therapy (ART). For concentrated epidemics, we calibrated Spectrum models to fi t vital registration data corrected for misclassifi cation of HIV deaths. In generalised epidemics, we minimised a loss function to select epidemic curves most consistent with prevalence data and demographic data for all-cause mortality. We analysed counterfactual scenarios for HIV to assess years of life saved through prevention of mother-to-child transmission (PMTCT) and ART. For tuberculosis, we analysed vital registration and verbal autopsy data to estimate mortality using cause of death ensemble modelling. We analysed data for corrected case-notifi cations, expert opinions on the case-detection rate, prevalence surveys, and estimated cause-specifi c mortality using Bayesian meta-regression to generate consistent trends in all parameters. We analysed malaria mortality and incidence using an updated cause of death database, a systematic analysis of verbal autopsy validation studies for malaria, and recent studies (2010-13) of incidence, drug resistance, and coverage of insecticide-treated bednets. Findings Globally in 2013, there were 1·8 million new HIV infections (95% uncertainty interval 1·7 million to 2·1 million), 29·2 million prevalent HIV cases (28·1 to 31·7), and 1·3 million HIV deaths (1·3 to 1·5). At the peak of the epidemic in 2005, HIV caused 1·7 million deaths (1·6 million to 1·9 million). Concentrated epidemics in Latin America and eastern Europe are substantially smaller than previously estimated. Through interventions including PMTCT and ART, 19·1 million life-years (16·6 million to 21·5 million) have been saved, 70·3% (65·4 to 76·1) in developing countries. From 2000 to 2011, the ratio of development assistance for health for HIV to years of life saved through intervention was US$4498 in developing countries. Including in HIV-positive individuals, all-form tuberculosis incidence was 7·5 million (7·4 million to 7·7 million), prevalence was 11·9 million (11·6 million to 12·2 million), and number of deaths was 1·4 million (1·3 million to 1·5 million) in 2013. In the same year and in only individuals who were HIV-negative, all-form tuberculosis incidence was 7·1 million (6·9 million to 7·3 million), prevalence was 11·2 million (10·8 million to 11·6 million), and number of deaths was 1·3 million (1·2 million to 1·4 million). Annualised rates of change (ARC) for incidence, prevalence, and death became negative after 2000. Tuberculosis in HIV-negative individuals disproportionately occurs in men and boys (versus women and girls); 64·0% of cases (63·6 to 64·3) and 64·7% of deaths (60·8 to 70·3). Globally, malaria cases and deaths grew rapidly from 1990 reaching a peak of 232 million cases (143 million to 387 million) in 2003 and 1·2 million deaths (1·1 million to 1·4 million) in 2004. Since 2004, child deaths from malaria in sub-Saharan Africa have decreased by 31·5% (15·7 to 44·1). Outside of Africa, malaria mortality has been steadily decreasing since 1990. Interpretation Our estimates of the number of people living with HIV are 18·7% smaller than UNAIDS's estimates in 2012. The number of people living with malaria is larger than estimated by WHO. Incidence rates for HIV, tuberculosis, and malaria have all decreased since 2000. At the global level, upward trends for malaria and HIV deaths have been reversed and declines in tuberculosis deaths have accelerated. 101 countries (74 of which are developing) still have increasing HIV incidence. Substantial progress since the Millennium Declaration is an encouraging sign of the effect of global action. Funding Bill & Melinda Gates Foundation.
AB - Background The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria through the formulation of Millennium Development Goal (MDG) 6. The Global Burden of Disease 2013 study provides a consistent and comprehensive approach to disease estimation for between 1990 and 2013, and an opportunity to assess whether accelerated progress has occured since the Millennium Declaration. Methods To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model appropriately modifi ed based on a systematic review of available studies of mortality with and without antiretroviral therapy (ART). For concentrated epidemics, we calibrated Spectrum models to fi t vital registration data corrected for misclassifi cation of HIV deaths. In generalised epidemics, we minimised a loss function to select epidemic curves most consistent with prevalence data and demographic data for all-cause mortality. We analysed counterfactual scenarios for HIV to assess years of life saved through prevention of mother-to-child transmission (PMTCT) and ART. For tuberculosis, we analysed vital registration and verbal autopsy data to estimate mortality using cause of death ensemble modelling. We analysed data for corrected case-notifi cations, expert opinions on the case-detection rate, prevalence surveys, and estimated cause-specifi c mortality using Bayesian meta-regression to generate consistent trends in all parameters. We analysed malaria mortality and incidence using an updated cause of death database, a systematic analysis of verbal autopsy validation studies for malaria, and recent studies (2010-13) of incidence, drug resistance, and coverage of insecticide-treated bednets. Findings Globally in 2013, there were 1·8 million new HIV infections (95% uncertainty interval 1·7 million to 2·1 million), 29·2 million prevalent HIV cases (28·1 to 31·7), and 1·3 million HIV deaths (1·3 to 1·5). At the peak of the epidemic in 2005, HIV caused 1·7 million deaths (1·6 million to 1·9 million). Concentrated epidemics in Latin America and eastern Europe are substantially smaller than previously estimated. Through interventions including PMTCT and ART, 19·1 million life-years (16·6 million to 21·5 million) have been saved, 70·3% (65·4 to 76·1) in developing countries. From 2000 to 2011, the ratio of development assistance for health for HIV to years of life saved through intervention was US$4498 in developing countries. Including in HIV-positive individuals, all-form tuberculosis incidence was 7·5 million (7·4 million to 7·7 million), prevalence was 11·9 million (11·6 million to 12·2 million), and number of deaths was 1·4 million (1·3 million to 1·5 million) in 2013. In the same year and in only individuals who were HIV-negative, all-form tuberculosis incidence was 7·1 million (6·9 million to 7·3 million), prevalence was 11·2 million (10·8 million to 11·6 million), and number of deaths was 1·3 million (1·2 million to 1·4 million). Annualised rates of change (ARC) for incidence, prevalence, and death became negative after 2000. Tuberculosis in HIV-negative individuals disproportionately occurs in men and boys (versus women and girls); 64·0% of cases (63·6 to 64·3) and 64·7% of deaths (60·8 to 70·3). Globally, malaria cases and deaths grew rapidly from 1990 reaching a peak of 232 million cases (143 million to 387 million) in 2003 and 1·2 million deaths (1·1 million to 1·4 million) in 2004. Since 2004, child deaths from malaria in sub-Saharan Africa have decreased by 31·5% (15·7 to 44·1). Outside of Africa, malaria mortality has been steadily decreasing since 1990. Interpretation Our estimates of the number of people living with HIV are 18·7% smaller than UNAIDS's estimates in 2012. The number of people living with malaria is larger than estimated by WHO. Incidence rates for HIV, tuberculosis, and malaria have all decreased since 2000. At the global level, upward trends for malaria and HIV deaths have been reversed and declines in tuberculosis deaths have accelerated. 101 countries (74 of which are developing) still have increasing HIV incidence. Substantial progress since the Millennium Declaration is an encouraging sign of the effect of global action. Funding Bill & Melinda Gates Foundation.
KW - Mortality for HIV
KW - HIV
KW - Tuberculosis
KW - Malaria
KW - Global Burden of Disease
UR - http://www.scopus.com/inward/record.url?scp=84907348191&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(14)60844-8
DO - 10.1016/S0140-6736(14)60844-8
M3 - Article
C2 - 25059949
SN - 0140-6736
VL - 384
SP - 1005
EP - 1070
JO - Lancet
JF - Lancet
IS - 9947
ER -